Cleveland Story

<div class='circular--portrait' style='background:#FF0F00;color: #FFFFF0;font-size:4em;'>CB</div>
CBLI -- USA Stock  

USD 4.73  0.30  5.96%

It looks like DiaMedica Therapeutics will continue to recover much faster as its share price surged up 5.93% today to Cleveland BioLabs's 13.7615%. As many rational traders are trying to avoid healthcare space, it makes sense to concentrate on Cleveland BioLabs a little further and understand how it stands against DiaMedica Therapeutics and other similar entities. We are going to examine some of the competitive aspects of both Cleveland and DiaMedica.
Published over a month ago
View all stories for Cleveland BioLabs | View All Stories
What should I drop first Cleveland (NASDAQ:CBLI) or DiaMedica Therapeutics?
By analyzing existing technical and fundamental indicators between Cleveland BioLabs and DiaMedica, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in DiaMedica with a short position in Cleveland BioLabs. Check out our pair correlation module for more information.

Let's begin by analyzing the assets. The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cleveland BioLabs has an asset utilization ratio of 3.03 percent. This implies that the company is making $0.0303 for each dollar of assets. An increasing asset utilization means that Cleveland BioLabs is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two companies, such as Cleveland or DiaMedica is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.

How important is Cleveland BioLabs's Liquidity

Cleveland BioLabs financial leverage refers to using borrowed capital as a funding source to finance Cleveland BioLabs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Cleveland BioLabs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between Cleveland BioLabs's total debt and its cash.

Correlation Between Cleveland and DiaMedica Therapeutics

In general, stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Cleveland BioLabs together with similar or unrelated positions with a negative correlation. For example, you can also add DiaMedica Therapeutics to your portfolio. If DiaMedica Therapeutics is not perfectly correlated to Cleveland BioLabs it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Cleveland BioLabs for example, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down. Please check pair correlation details between CBLI and DMAC for more information.


Are you currently holding both Cleveland BioLabs and DiaMedica Therapeutics in your portfolio? Please note if you are using this as a pair-trade strategy between Cleveland BioLabs and DiaMedica Therapeutics, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses.

Sale by Yakov Kogan of 300 shares of Cleveland BioLabs

Legal trades by Cleveland BioLabs insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Cleveland BioLabs insider trading alert for sale of common stock by Yakov Kogan, COO Secretary, on 28th of April 2020. This event was filed by Cleveland Biolabs Inc with SEC on 2010-02-02. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is driving Cleveland BioLabs Investor Appetite?

Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Revenue Breakdown

Lets now check Cleveland BioLabs revenue. Based on the latest financial disclosure, Cleveland BioLabs reported 631.84 K of revenue. This is 99.99% lower than that of the Healthcare sector and 99.91% lower than that of the Biotechnology industry. The revenue for all United States stocks is 99.99% higher than that of Cleveland BioLabs. As for DiaMedica Therapeutics we see revenue of 447.37 K, which is 99.94% lower than that of the Biotechnology

742.9 M
Sector742.91 Million99.85

Our take on today Cleveland BioLabs rise

Current value at risk is at -8.55. Cleveland BioLabs is displaying above-average volatility over the selected time horizon. Investors should scrutinize Cleveland BioLabs independently to ensure intended market timing strategies are aligned with expectations about Cleveland BioLabs volatility.

The Current Takeaway on Cleveland BioLabs Investment

While many of the other players under the biotechnology industry are still a bit expensive, Cleveland BioLabs may offer a potential longer-term growth to stockholders. Taking everything into account, as of the 27th of December 2020, we believe that Cleveland BioLabs is currently overvalued with high chance of distress in the next two years. Our current 30 days buy vs. sell advice on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Cleveland BioLabs. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to